Welcome to our dedicated page for Conavi Medical news (Ticker: CNVIF), a resource for investors and traders seeking the latest updates and insights on Conavi Medical stock.
Conavi Medical Corp. (CNVIF) is a commercial-stage medical device company focused on intravascular and intracoronary imaging technologies used during minimally invasive cardiovascular procedures. Its news flow centers on the development, regulatory progress, and commercialization of the Novasight Hybrid™ System, a patented platform that combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single system for simultaneous, co-registered imaging of coronary arteries.
On this page, readers can follow company announcements related to the Novasight Hybrid™ platform, including updates on the next-generation Novasight Hybrid™ IVUS/OCT intravascular imaging system and its submission to the U.S. Food and Drug Administration (FDA) for 510(k) clearance for coronary applications. Conavi’s news often highlights validation testing with interventional cardiologists, participation in major cardiology conferences such as Transcatheter Cardiovascular Therapeutics (TCT), and educational sessions on hybrid IVUS/OCT imaging in complex percutaneous coronary interventions (PCI).
Investors and clinicians can also track peer-reviewed publication highlights referenced by Conavi, including case reports and large-scale analyses that discuss the role of intravascular imaging in PCI, as well as commentary on international guideline updates that recommend IVUS or OCT guidance in complex coronary cases. Financial and corporate news items may cover public equity financings, non-dilutive funding agreements such as the Life Sciences Scale-Up Fund in Ontario, and leadership or organizational updates that the company associates with its commercialization plans.
By monitoring this CNVIF news feed, users can see how Conavi describes the evolution of its hybrid imaging technology, its regulatory milestones, and its efforts to prepare manufacturing and operational infrastructure for broader clinical use of the Novasight Hybrid™ System.
Conavi Medical (TSXV: CNVI) reported its fiscal Q1 2025 results, marking its first quarter as a public company. The company raised $10.6 million CAD through a concurrent private placement and completed a reverse takeover of Titan Medical Inc.
Revenue reached $8.6 million, up from $0.7 million year-over-year, primarily due to an $8.4 million milestone payment from East Ocean Medical following Chinese regulatory approval. Operating expenses increased to $6.8 million from $5.1 million, with R&D expenses at $4.7 million. The company reported a net loss of $7.6 million ($0.19 per share).
Key developments include:
- Completion of next-generation Novasight design freeze
- Initiation of usability testing and system validation
- FDA submission planned for Q3 2025
- Cash position of $5.1 million as of December 31, 2024